Abbott Laboratories ABT:NYSE

RT Quote | Last NYSE, VOL From CTA | USD

Last | 12:59 PM EDT

104.20

-0.03 (-0.03%)

Volume

1,610,791

52 week range

89.67 - 121.64

Open104.15
Day High104.37
Day Low103.58
Prev Close104.23
52 Week High121.64
52 Week High Date03/08/24
52 Week Low89.67
52 Week Low Date10/12/23

Key Stats

Market Cap181.27B
Shares Out1.74B
10 Day Average Volume6.44M
Dividend2.20
Dividend Yield2.11%
Beta0.74
YTD % Change-5.28

KEY STATS

Open104.15
Day High104.37
Day Low103.58
Prev Close104.23
52 Week High121.64
52 Week High Date03/08/24
52 Week Low89.67
52 Week Low Date10/12/23
Market Cap181.27B
Shares Out1.74B
10 Day Average Volume6.44M
Dividend2.20
Dividend Yield2.11%
Beta0.74
YTD % Change-5.28

RATIOS/PROFITABILITY

EPS (TTM)3.22
P/E (TTM)32.36
Fwd P/E (NTM)21.88
EBITDA (TTM)9.841B
ROE (TTM)14.85%
Revenue (TTM)40.326B
Gross Margin (TTM)55.25%
Net Margin (TTM)13.96%
Debt To Equity (MRQ)37.58%

EVENTS

Earnings Date07/18/2024(est)
Ex Div Date04/12/2024
Div Amount0.55
Split Date-
Split Factor-

Latest On Abbott Laboratories

Citi elevates GE Healthcare to a top pick. Why we're not buying more shares yetMay 22, 2024CNBC.com
We're encouraged by an activist's buy of an Abbott rival amid baby formula suitsMay 21, 2024CNBC.com
Lightning Round: Stay away from Canada Goose, says Jim CramerMay 20, 2024CNBC.com
Cramer's Lightning Round: 'Stay away' from Canada GooseMay 20, 2024CNBC.com
PEG ratio can help inform stock buying decisions. What it is and how to use itMay 12, 2024CNBC.com

Content From Our Affiliates

Abbott price target lowered to $119 from $128 at CitiMay 22, 2024TipRanks
Buy Rating Affirmed for Abbott Laboratories Based on Strong EP Business and Strategic Growth ProspectsMay 20, 2024TipRanks
Abbott call volume above normal and directionally bullishMay 16, 2024TipRanks
Buy Recommendation for Abbott Laboratories Backed by Strong Sales Growth and Promising PipelineMay 16, 2024TipRanks
FDA posts Class I recall of Abbott HeartMate 3 LVAS implant kitMay 15, 2024TipRanks

Profile

Abbott Laboratories is a global healthcare company. The Company is engaged in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. The...

Robert Ford

Chairman of the Board, Chief Executive Officer

Philip Boudreau

Chief Financial Officer, Senior Vice President - Finance

Louis Morrone

Executive Vice President - Core Diagnostics

Daniel Salvadori

Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products

Hubert Allen

Executive Vice President, General Counsel, Secretary

Address

100 Abbott Park Road, Abbot Park

Abbott Park, IL

60064-3500

United States

https://www.abbott.com

Top Peers

SYMBOL	LAST	CHG	%CHG
TMO Thermo Fisher Scientific Inc	581.92	-3.11	-0.53%
DHR Danaher Corp	261.71	+0.31	+0.12%
MDT Medtronic PLC	81.83	+0.45	+0.55%
SYK Stryker Corp	335.76	+5.64	+1.71%
BSX Boston Scientific Corp	75.74	+1.36	+1.83%